All articles tagged with #mrna vaccines
The FDA has reversed its earlier stance and agreed to review Moderna’s updated mRNA flu vaccine, with plans for full approval in adults 50–64 and accelerated approval for those 65 and older, plus a post-marketing study in older adults. A decision is expected by August 5, and Moderna shares rose on the news.
Sanofi has deprioritized its phase 1 mRNA seasonal flu program, scrapping the effort as part of a broader strategic shift, while continuing to pursue an mRNA vaccine for an H5 pandemic and focusing on established influenza vaccines (Fluzone High-Dose, Flublok). The influenza/COVID vaccine franchise generated €2.3 billion last year, a 6% decline from 2024 amid lower US immunization rates, and the company underscored a multi‑platform vaccine strategy, including the Dynavax acquisition, as its growth path.
Stanford researchers have identified that rare cases of heart inflammation post-mRNA COVID-19 vaccination are driven by immune responses involving cytokines CXCL10 and IFN-gamma, and found that the soy-derived compound genistein may help reduce this inflammation, offering insights into safer vaccine strategies.
Stanford researchers have uncovered a biological mechanism explaining why rare cases of myocarditis occur after mRNA COVID-19 vaccination, identifying two cytokines, CXCL10 and IFN-gamma, as key drivers of heart inflammation, and suggesting that cytokine inhibitors or dietary supplements like genistein could potentially reduce this risk.
A Stanford Medicine study indicates that mRNA COVID-19 vaccines can cause myocarditis, especially in young men and adolescents, with a very low incidence rate, but most cases recover fully and the benefits of vaccination outweigh the risks.
A recent study suggests that Covid mRNA vaccines may boost the immune response in cancer patients, significantly increasing their median survival time and potentially revolutionizing cancer treatment by repurposing existing vaccines to enhance immune system activation, though further research is needed to confirm causation.
A study suggests that mRNA COVID vaccines like Pfizer and Moderna may enhance survival rates in cancer patients undergoing immunotherapy, potentially 'priming' the immune system to fight cancer more effectively, though more research is needed; the vaccines remain primarily important for preventing COVID-19 complications.
A study suggests that mRNA COVID-19 vaccines like Pfizer and Moderna may enhance survival rates in cancer patients undergoing immunotherapy, potentially 'priming' the immune system to fight cancer more effectively, though more research is needed; the vaccine's primary benefit remains COVID-19 prevention.
New research suggests that COVID-19 mRNA vaccines may boost survival rates in patients with advanced lung and skin cancers when administered within 100 days of starting immunotherapy, potentially paving the way for a universal cancer vaccine. The findings, based on patient data and mouse experiments, are preliminary but promising, prompting plans for further clinical trials.
Recent studies suggest that COVID-19 mRNA vaccines may also help the immune system recognize and attack cancer tumors, potentially improving survival rates and transforming cancer treatment, though further clinical trials are needed to confirm these findings.
A study by the University of Texas MD Anderson and the University of Florida found that mRNA COVID-19 vaccines not only protect against the virus but also nearly double the median survival time of cancer patients by boosting the immune system.
COVID-19 mRNA vaccines enhance the effectiveness of immune checkpoint inhibitors in cancer treatment by stimulating innate and adaptive immune responses, increasing tumor PD-L1 expression, and potentially restoring immune sensitivity in 'cold' tumors, leading to improved survival outcomes in patients with NSCLC and melanoma.
A study presented at the 2025 European Society for Medical Oncology Congress suggests that COVID-19 mRNA vaccines may enhance survival in patients with advanced lung and melanoma cancers by sensitizing tumors to immunotherapy, nearly doubling median survival times when administered within 100 days of starting immune checkpoint inhibitors.
Researchers at MD Anderson Cancer Center presented at ESMO 2025 that mRNA COVID-19 vaccines significantly boost the efficacy of cancer immunotherapy, especially in tumors with low baseline immune activity, by enhancing immune responses and increasing tumor susceptibility to checkpoint blockade, potentially transforming cancer treatment protocols.
Early research from Penn Medicine suggests that new mRNA vaccines could prevent food and seasonal allergies by stopping allergens from triggering immune reactions and inflammation, showing promise for future allergy treatments.